RESUMEN
Antibody-drug conjugates (ADCs) are novel drugs consisting of monoclonal antibodies targeting tumor-specific or tumor-associated antigens coupled with different numbers of payloads via linkers. ADCs have shown promising clinical benefits in the treatment of a variety of malignancies. Small-cell lung cancer (SCLC) is a hypo-differentiated neuroendocrine tumor with an extremely high degree of malignancy. Although SCLC is sensitive to radiotherapy and chemotherapy, it has a poor prognosis due to characteristics such as early susceptibility to metastasis and recurrence. Progress in the treatment of SCLC is very limited, and more durable and effective therapies should be developed to improve prognosis. However, the progress of SCLC-related therapeutic agents has been limited by the lack of specific molecular targets. This article reviews the basic principles and mechanisms of ADCs, highlights the research progress of relevant drugs against some targets in SCLC, and summarizes new targets that may be developed as targeted drugs.
RESUMEN
@#The occurrence of cholestatic liver injury is accompanied by the alterations of hepatocyte polarization and bile acid homeostasis. Located in epithelial cells, tight junctions(TJs)are a special barrier structure which are important in maintaining permeability and bile acid homeostasis. Based on the fully analysis and discussion of TJs, the latest therapeutic drugs for cholestasis were summaried, which may provide new perspectives and potential therapeutic agents for the treatment of cholestatic liver injury.
RESUMEN
Type 2 diabete, caused by inadequate secretion of insulin and insulin resistance in tissues and organs, is also called non insulin dependent diabete. At present, over 90% diabetes is type 2 diabete which is seriously harmful to human health, however, the current clinical application of chemical synthetic medicines have different degrees of side effects. Therefore, the study of components with antidiabetic activity acting on different targets from the natural products with low toxicity has become a focus of current research. The new targets, such as PTP1B, DPP-IV, PPAR, and AMPK, were discovered in recent years. In this paper, active components in natural products on new targets for diabetes are reviewed, so as to provide the reference for the further research of diabetes.